Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation

Lan Zhong,1,2 Rutie Yin,1,2 Liang Song1,2 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, People’s Republic of China; 2Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Minis...

Full description

Bibliographic Details
Main Authors: Zhong L, Yin R, Song L
Format: Article
Language:English
Published: Dove Medical Press 2023-03-01
Series:Pharmacogenomics and Personalized Medicine
Subjects:
parpi resistance
brca1 mutation
ovarian carcinoma
circulating tumor dna
sequencing  
Online Access:https://www.dovepress.com/resistance-to-parp-inhibitors-after-first-line-platinum-based-chemothe-peer-reviewed-fulltext-article-PGPM

Internet

https://www.dovepress.com/resistance-to-parp-inhibitors-after-first-line-platinum-based-chemothe-peer-reviewed-fulltext-article-PGPM

Similar Items